Skip to main content
Top
Published in: BMC Infectious Diseases 1/2019

Open Access 01-12-2019 | Tuberculosis | Research article

Prevalence of rifampicin resistant Mycobacterium tuberculosis among presumptive tuberculosis patients in selected governmental hospitals in Addis Ababa, Ethiopia

Authors: Balew Arega, Fiqrte Menbere, Yitagesu Getachew

Published in: BMC Infectious Diseases | Issue 1/2019

Login to get access

Abstract

Background

Rapid detection of rifampicin resistance is essential for early management and prevention of transmission of multidrug-resistant tuberculosis (MDR-TB). We studied the prevalence of rifampicin resistance of Mycobacterium tuberculosis (MTB) among presumptive TB patients in Addis Ababa, Ethiopia.

Methods

A retrospective cross sectional study was conducted in three referral hospitals and the regional laboratory in Addis Ababa city from March 2015 to October 2017. Data was collected by data-extraction sheet from registration books. It was analyzed using SPSS version 20. Statistically significant association was taken with P < 0.05.

Results

A total of 12,414 (11,672 adults and 742 paediatrics) TB presumptive patients were included in the study. The overall prevalence of TB was 15.11% (1876/12414) in all age groups and 13.6%(101/742) among paediatric population. Rifampicin resistant TB was 9.9% (186/1876) in all TB confirmed cases and 7.9% (8/101) in paediatric TB patients. The prevalence of rifampicin resistant TB among new and previously treated was 7.6 and 27.4%, respectively. Sex (being female) and previous TB treatment were significantly associated with rifampicin resistant TB.

Conclusions

Rifampicin-resistant TB is prevalent both among adult and paediatric TB patients. The strong association of rifampicin resistance with previous treatment in this study suggests the need to improve and monitor the treatment to limit the emergence of drug resistant TB.
Literature
1.
go back to reference WHO/IUATLD. Global Project on Anti-tuberculosis Drug Resistance Surveillance. Anti-Tuberculosis Drug Resistance in the World. Geneva: WHO; 2008. WHO/IUATLD. Global Project on Anti-tuberculosis Drug Resistance Surveillance. Anti-Tuberculosis Drug Resistance in the World. Geneva: WHO; 2008.
2.
3.
go back to reference Zignol M, Dean AS, Falzon D, et al. Twenty Years of Global Surveillance of Anti tuberculosis-Drug Resistance. N Engl J Med. 2016;375:11.CrossRef Zignol M, Dean AS, Falzon D, et al. Twenty Years of Global Surveillance of Anti tuberculosis-Drug Resistance. N Engl J Med. 2016;375:11.CrossRef
4.
go back to reference Shenoi S, Friedland G. Extensively drug-resistant tuberculosis: a new face to an old pathogen. AnnuRev Med. 2009;60:307–20.CrossRef Shenoi S, Friedland G. Extensively drug-resistant tuberculosis: a new face to an old pathogen. AnnuRev Med. 2009;60:307–20.CrossRef
5.
go back to reference Snider DE, Kelly GD, Cauthen GM, et al. Infection and disease among contacts of tuberculosis cases with drug resistant and drug susceptible bacilli. Am Rev Respir Dis. 1985;132:125–32.PubMed Snider DE, Kelly GD, Cauthen GM, et al. Infection and disease among contacts of tuberculosis cases with drug resistant and drug susceptible bacilli. Am Rev Respir Dis. 1985;132:125–32.PubMed
6.
go back to reference Riordan P, Schwab U, Logan S, et al. Rapid molecular detection of rifampicin resistance facilitates early diagnosis and treatment of multi-drug resistant tuberculosis. PLoS ONE. 2008;3:1–7.CrossRef Riordan P, Schwab U, Logan S, et al. Rapid molecular detection of rifampicin resistance facilitates early diagnosis and treatment of multi-drug resistant tuberculosis. PLoS ONE. 2008;3:1–7.CrossRef
7.
go back to reference WHO: treatment guidelines for drug-resistant tuberculosis, 2016 update. October 2016 revision. WHO: treatment guidelines for drug-resistant tuberculosis, 2016 update. October 2016 revision.
8.
go back to reference WHO. Rapid implementation of the Xpert MTB/RIF diagnostic test. Geneva: WHO; 2011. WHO. Rapid implementation of the Xpert MTB/RIF diagnostic test. Geneva: WHO; 2011.
9.
go back to reference WHO: Xpert MTB/RIF assay for the diagnosis of TB Meeting Report 2016. WHO: Xpert MTB/RIF assay for the diagnosis of TB Meeting Report 2016.
10.
go back to reference Ethiopia Federal Ministry of Health. Guideline for program and clinical management of drug-resistant tuberculosis. 5th ed. Addis Ababa: FMOH; 2009. Ethiopia Federal Ministry of Health. Guideline for program and clinical management of drug-resistant tuberculosis. 5th ed. Addis Ababa: FMOH; 2009.
11.
go back to reference Kebede AH, Alebachew Z, Tsegaye F, et al. The first Ethiopian National Population-based TB prevalence survey. Int J Tuberc Lung Dis. 2014;18(6):635–9.CrossRef Kebede AH, Alebachew Z, Tsegaye F, et al. The first Ethiopian National Population-based TB prevalence survey. Int J Tuberc Lung Dis. 2014;18(6):635–9.CrossRef
12.
go back to reference Eshetie S, Gizachew M, Dagnew M. Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis. BMC Infect Dis. 2017;17:219.CrossRef Eshetie S, Gizachew M, Dagnew M. Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis. BMC Infect Dis. 2017;17:219.CrossRef
13.
go back to reference WHO. Drug-resistant tuberculosis now at record levels. Geneva: WHO press; 2010. WHO. Drug-resistant tuberculosis now at record levels. Geneva: WHO press; 2010.
14.
go back to reference Implementation GuIdelIne for Gene Xpert mtB/rIf assay In ethIopIa June, 2014 | Addis Ababa. Implementation GuIdelIne for Gene Xpert mtB/rIf assay In ethIopIa June, 2014 | Addis Ababa.
15.
go back to reference Alemu A, Tesfay E, Yaregal Z, et al. Status of Xpert MTB/RIF Assay Implementation in Ethiopia. J Infect Dis. 2017;5:6. Alemu A, Tesfay E, Yaregal Z, et al. Status of Xpert MTB/RIF Assay Implementation in Ethiopia. J Infect Dis. 2017;5:6.
16.
go back to reference Hordofa MW, Adela TB. Prevalence of Refampcin mono resistant Mycobacterium tuberculosis among suspected cases attending at Yirgalem hospital. Clin Med Res. 2015;4(3):75–8.CrossRef Hordofa MW, Adela TB. Prevalence of Refampcin mono resistant Mycobacterium tuberculosis among suspected cases attending at Yirgalem hospital. Clin Med Res. 2015;4(3):75–8.CrossRef
17.
go back to reference Assefa D, Cherinet Y, Negussie A. Xpert MTB/RIF assay for diagnosis of pulmonary tuberculosis in sputum specimens in remote health care facility. BMC Microbiol. 2015;15:220.CrossRef Assefa D, Cherinet Y, Negussie A. Xpert MTB/RIF assay for diagnosis of pulmonary tuberculosis in sputum specimens in remote health care facility. BMC Microbiol. 2015;15:220.CrossRef
18.
go back to reference Jaleta FK, Gizachew M, Gelaw B, et al. Rifampicin-resistant Mycobacterium tuberculosis among tuberculosis-presumptive cases at University of Gondar Hospital, northwest Ethiopia. Infect Drug Resist. 2017;10:185–92.CrossRef Jaleta FK, Gizachew M, Gelaw B, et al. Rifampicin-resistant Mycobacterium tuberculosis among tuberculosis-presumptive cases at University of Gondar Hospital, northwest Ethiopia. Infect Drug Resist. 2017;10:185–92.CrossRef
19.
go back to reference Mulu W, Abera B, Yimer M, et al. Rifampicin-resistance pattern of Mycobacterium tuberculosis and associated factors among presumptive tuberculosis patients referred to Debre Markos referral hospital, Ethiopia: a cross-sectional study. BMC Res Notes. 2017;10:8.CrossRef Mulu W, Abera B, Yimer M, et al. Rifampicin-resistance pattern of Mycobacterium tuberculosis and associated factors among presumptive tuberculosis patients referred to Debre Markos referral hospital, Ethiopia: a cross-sectional study. BMC Res Notes. 2017;10:8.CrossRef
20.
go back to reference Nicol MP, Workman L, Isaacs W, et al. Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study. Lancet Infect Dis. 2011;11(11):819–24.CrossRef Nicol MP, Workman L, Isaacs W, et al. Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study. Lancet Infect Dis. 2011;11(11):819–24.CrossRef
21.
go back to reference Sekadde MP, Wobudeya E, Joloba ML, et al. Evaluation of the Xpert MTB/RIF test for the diagnosis of childhood pulmonary tuberculosis in Uganda: a cross-sectional diagnostic study. BMC Infect Dis. 2013;13:133.CrossRef Sekadde MP, Wobudeya E, Joloba ML, et al. Evaluation of the Xpert MTB/RIF test for the diagnosis of childhood pulmonary tuberculosis in Uganda: a cross-sectional diagnostic study. BMC Infect Dis. 2013;13:133.CrossRef
22.
go back to reference Workalemahuet B, Berg S, Tsegaye W, et al. Genotype diversity of Mycobacterium isolates from children in Jimma, Ethiopia. BMC Res Notes. 2013;6:352.CrossRef Workalemahuet B, Berg S, Tsegaye W, et al. Genotype diversity of Mycobacterium isolates from children in Jimma, Ethiopia. BMC Res Notes. 2013;6:352.CrossRef
23.
go back to reference Audu ES, Gambo MS, Yakubu AA. Rifampicin resistant mycobacterium tuberculosis in Nasarawa State, Nigeria. Niger J Basic Clin Sci. 2017;14:21–5.CrossRef Audu ES, Gambo MS, Yakubu AA. Rifampicin resistant mycobacterium tuberculosis in Nasarawa State, Nigeria. Niger J Basic Clin Sci. 2017;14:21–5.CrossRef
24.
go back to reference Hamusse SD, Teshome D, Suaudi MH. Primary and secondary anti-tuberculosis drug resistance in Hitossa District of Arsi Zone, Oromia Regional State, Central Ethiopia. BMC Public Health. 2016;16:59.CrossRef Hamusse SD, Teshome D, Suaudi MH. Primary and secondary anti-tuberculosis drug resistance in Hitossa District of Arsi Zone, Oromia Regional State, Central Ethiopia. BMC Public Health. 2016;16:59.CrossRef
25.
go back to reference Tessema B, Beer J, Merker M, et al. Molecular epidemiology and transmission dynamics of Mycobacterium tuberculosis in Northwest Ethiopia: new phylogenetic lineages found in Northwest Ethiopia. BMC Infect Dis. 2013;13:1.CrossRef Tessema B, Beer J, Merker M, et al. Molecular epidemiology and transmission dynamics of Mycobacterium tuberculosis in Northwest Ethiopia: new phylogenetic lineages found in Northwest Ethiopia. BMC Infect Dis. 2013;13:1.CrossRef
26.
go back to reference Mulisaa G, Workneha T, Hordofa N, et al. Multidrug-resistant Mycobacterium tuberculosis and associated risk factors in Oromia Region of Ethiopia. Int J Infect Dis. 2015;39:57–61.CrossRef Mulisaa G, Workneha T, Hordofa N, et al. Multidrug-resistant Mycobacterium tuberculosis and associated risk factors in Oromia Region of Ethiopia. Int J Infect Dis. 2015;39:57–61.CrossRef
27.
go back to reference Nigus DM, Lingerew WM, Beyene BA, et al. Prevalence of multi drug resistant tuberculosis among presumptive multi drug resistant tuberculosis cases in Amhara National Regional State, Ethiopia. J Mycobac Dis. 2014;4:152.CrossRef Nigus DM, Lingerew WM, Beyene BA, et al. Prevalence of multi drug resistant tuberculosis among presumptive multi drug resistant tuberculosis cases in Amhara National Regional State, Ethiopia. J Mycobac Dis. 2014;4:152.CrossRef
28.
go back to reference Tao N, He X. Zhang X etal drug-resistant tuberculosis among children, China, 2006–2015. Emerg Infect Dis. 2017;23(11):1805.CrossRef Tao N, He X. Zhang X etal drug-resistant tuberculosis among children, China, 2006–2015. Emerg Infect Dis. 2017;23(11):1805.CrossRef
29.
30.
go back to reference Vandepitte WP, Rattanasataporn R, Treeratweeraphong V. Drug-Resistant Tuberculosis Among Urban Thai Children: A 10-Year Review: Drug-Resistant Tuberculosis In Urban Thai Children. A 10-YEAR REVIEW. South East Asian J Trop Med public health. 2015;46(5):893–9. Vandepitte WP, Rattanasataporn R, Treeratweeraphong V. Drug-Resistant Tuberculosis Among Urban Thai Children: A 10-Year Review: Drug-Resistant Tuberculosis In Urban Thai Children. A 10-YEAR REVIEW. South East Asian J Trop Med public health. 2015;46(5):893–9.
31.
go back to reference Zignol M, Sismanidis C, Falzon D. WHO, Multidrug-resistant tuberculosis in children: evidence from global surveillance. Eur Respir J. 2013;42:701–7.CrossRef Zignol M, Sismanidis C, Falzon D. WHO, Multidrug-resistant tuberculosis in children: evidence from global surveillance. Eur Respir J. 2013;42:701–7.CrossRef
33.
go back to reference World Health Organization. Treatment of tuberculosis: guidelines, 4thedn. WHO/HTM/TB/2009420; 2009. World Health Organization. Treatment of tuberculosis: guidelines, 4thedn. WHO/HTM/TB/2009420; 2009.
34.
go back to reference Rachow A, Clowes P, Saathoff E, Mtafya B, Michael E, Ntinginya EN, et al. Increased and expedited case detection by Xpert MTB/RIF assay in childhood tuberculosis: a prospective cohort study. Clin Infect Dis. 2012;54:1388–96.CrossRef Rachow A, Clowes P, Saathoff E, Mtafya B, Michael E, Ntinginya EN, et al. Increased and expedited case detection by Xpert MTB/RIF assay in childhood tuberculosis: a prospective cohort study. Clin Infect Dis. 2012;54:1388–96.CrossRef
35.
go back to reference Swaminathan S, Banu Rekha B. Pediatric Tuberculosis: Global Overview and Challenges. Clinical Infectious Diseases. 2010;50(S3):S184–94.CrossRef Swaminathan S, Banu Rekha B. Pediatric Tuberculosis: Global Overview and Challenges. Clinical Infectious Diseases. 2010;50(S3):S184–94.CrossRef
36.
go back to reference Divani N, Zangaladze E, Volkova N, et al. High prevalence of multi-drug resistant tuberculosis in Georgia. Int J Infect Dis. 2008;12:635–44.CrossRef Divani N, Zangaladze E, Volkova N, et al. High prevalence of multi-drug resistant tuberculosis in Georgia. Int J Infect Dis. 2008;12:635–44.CrossRef
37.
go back to reference Toungoussova S, Caugant DA, Sandven P, Mariandyshev AO, Bjune G. Drug resistance of Mycobacterium tuberculosis strains isolated from patients with pulmonary tuberculosis in archangels, Russia. Int J Tuberc Lung Dis. 2002;6(5):406–14.PubMed Toungoussova S, Caugant DA, Sandven P, Mariandyshev AO, Bjune G. Drug resistance of Mycobacterium tuberculosis strains isolated from patients with pulmonary tuberculosis in archangels, Russia. Int J Tuberc Lung Dis. 2002;6(5):406–14.PubMed
38.
go back to reference Lockman S, Kruuner A, Binkin N, Levina K, Wang Y, Danilovitsh M, et al. Clinical outcomes of Estonian patients with primary multi- drug-resistant versus drug-susceptible tuberculosis. Clin Infect Dis. 2001;32:373–80.CrossRef Lockman S, Kruuner A, Binkin N, Levina K, Wang Y, Danilovitsh M, et al. Clinical outcomes of Estonian patients with primary multi- drug-resistant versus drug-susceptible tuberculosis. Clin Infect Dis. 2001;32:373–80.CrossRef
39.
go back to reference Bati J, Legesse M, Girmay MG. Community’s knowledge, attitudes and practices about tuberculosis in Itang special district, Gambella Region, South Western Ethiopia. BMC Public Health. 2013;13:734.CrossRef Bati J, Legesse M, Girmay MG. Community’s knowledge, attitudes and practices about tuberculosis in Itang special district, Gambella Region, South Western Ethiopia. BMC Public Health. 2013;13:734.CrossRef
40.
go back to reference Storla DG, Yimer S, Bjune AG. A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health. 2008;8:15.CrossRef Storla DG, Yimer S, Bjune AG. A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health. 2008;8:15.CrossRef
41.
go back to reference Wondimu T, W/Michael K, et al. Delay in initiating tuberculosis treatment and factors associated among pulmonary tuberculosis patients in East Wollega, Western Ethiopia. Ethiop J Health Dev. 2007;21(2):148–56.CrossRef Wondimu T, W/Michael K, et al. Delay in initiating tuberculosis treatment and factors associated among pulmonary tuberculosis patients in East Wollega, Western Ethiopia. Ethiop J Health Dev. 2007;21(2):148–56.CrossRef
Metadata
Title
Prevalence of rifampicin resistant Mycobacterium tuberculosis among presumptive tuberculosis patients in selected governmental hospitals in Addis Ababa, Ethiopia
Authors
Balew Arega
Fiqrte Menbere
Yitagesu Getachew
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2019
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-019-3943-1

Other articles of this Issue 1/2019

BMC Infectious Diseases 1/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine